TY - JOUR
T1 - Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma
T2 - Which Patients Benefit the Most from Nodal Evaluation?
AU - Sahara, Kota
AU - Tsilimigras, Diamantis I.
AU - Merath, Katiuscha
AU - Bagante, Fabio
AU - Guglielmi, Alfredo
AU - Aldrighetti, Luca
AU - Weiss, Matthew
AU - Bauer, Todd W.
AU - Alexandrescu, Sorin
AU - Poultsides, George A.
AU - Maithel, Shishir K.
AU - Marques, Hugo P.
AU - Martel, Guillaume
AU - Pulitano, Carlo
AU - Shen, Feng
AU - Soubrane, Olivier
AU - Koerkamp, B. Groot
AU - Matsuyama, Ryusei
AU - Endo, Itaru
AU - Pawlik, Timothy M.
N1 - Publisher Copyright:
© 2019, Society of Surgical Oncology.
PY - 2019/9/15
Y1 - 2019/9/15
N2 - Background: Although lymph node metastasis (LNM) is an important prognostic indicator for patients with intrahepatic cholangiocarcinoma (ICC), the benefit and indication for lymphadenectomy remain unclear. Methods: Patients diagnosed with ICC between 1990 and 2016 were identified in the international multi-institutional dataset. To determine the survival benefit from lymphadenectomy, the therapeutic index was calculated by multiplying the frequency of LNM in a particular group of patients by the 3-year cancer-specific survival (CSS) rate of patients with LNM in that subgroup. Results: Among 471 patients who met the inclusion criteria, approximately half had LNM (n = 205, 43.5%). The median number of resected and metastatic LNs were 4 [interquartile range (IQR) 2–8] and 0 (IQR 0–1), respectively. Three-year CSS in the entire cohort was 29.9%, reflecting a therapeutic index value of 13.0. The therapeutic index was lower among patients with major vascular invasion (5.4), preoperative carcinoembryonic antigen (CEA) > 5.0 (8.2), and LNM in areas other than the hepatoduodenal ligament (5.2). Of note, a therapeutic index difference of more than 10 points was noted only when examining the number of LNs harvested [1–2 (4.1) vs. 3–6 (16.1) vs. ≥ 7 (17.8)]. Conclusion: The survival benefit derived from lymphadenectomy was poor among patients with major vascular invasion, CEA > 5.0, and LNM in areas other than the hepatoduodenal ligament. Resection of three or more LNs was associated with the highest therapeutic value among patients with LNM.
AB - Background: Although lymph node metastasis (LNM) is an important prognostic indicator for patients with intrahepatic cholangiocarcinoma (ICC), the benefit and indication for lymphadenectomy remain unclear. Methods: Patients diagnosed with ICC between 1990 and 2016 were identified in the international multi-institutional dataset. To determine the survival benefit from lymphadenectomy, the therapeutic index was calculated by multiplying the frequency of LNM in a particular group of patients by the 3-year cancer-specific survival (CSS) rate of patients with LNM in that subgroup. Results: Among 471 patients who met the inclusion criteria, approximately half had LNM (n = 205, 43.5%). The median number of resected and metastatic LNs were 4 [interquartile range (IQR) 2–8] and 0 (IQR 0–1), respectively. Three-year CSS in the entire cohort was 29.9%, reflecting a therapeutic index value of 13.0. The therapeutic index was lower among patients with major vascular invasion (5.4), preoperative carcinoembryonic antigen (CEA) > 5.0 (8.2), and LNM in areas other than the hepatoduodenal ligament (5.2). Of note, a therapeutic index difference of more than 10 points was noted only when examining the number of LNs harvested [1–2 (4.1) vs. 3–6 (16.1) vs. ≥ 7 (17.8)]. Conclusion: The survival benefit derived from lymphadenectomy was poor among patients with major vascular invasion, CEA > 5.0, and LNM in areas other than the hepatoduodenal ligament. Resection of three or more LNs was associated with the highest therapeutic value among patients with LNM.
UR - http://www.scopus.com/inward/record.url?scp=85066604037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066604037&partnerID=8YFLogxK
U2 - 10.1245/s10434-019-07483-9
DO - 10.1245/s10434-019-07483-9
M3 - Article
C2 - 31152272
AN - SCOPUS:85066604037
VL - 26
SP - 2959
EP - 2968
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 9
ER -